IVD CDMO vs CRO vs CMO: Which Partner Do You Need at Each Development Stage?

06Jul 2026

Knowledge IVDCDMO Team Comments: 0

The difference between an IVD CDMO, CRO and CMO is not simply the range of services listed on a supplier’s website. Each type of partner is designed to remove a different category of program risk.

An IVD CDMO is most valuable when the product or manufacturing process is still being developed. A CRO becomes critical when the remaining uncertainty concerns specimens, study execution, clinical evidence or statistical validity. A CMO is usually the right choice when the design is sufficiently mature and the main objective is repeatable, compliant and economical production.

Most regulated in vitro diagnostic programs eventually need all three capabilities. The real decision is not which acronym is “best,” but which organization should lead at a particular stage—and how the technical, clinical and manufacturing work should connect.

The shortest practical answer is:

Choose an IVD CDMO when the assay, cartridge, instrument, software, packaging or manufacturing process still requires development.
Choose an IVD CRO when you need qualified specimens, study sites, clinical operations, data management, biostatistics or a regulatory-grade performance study.
Choose an IVD CMO when the design and production specifications are substantially established and you need routine manufacturing capacity.
Use an integrated or hybrid model when product development, evidence generation and manufacturing scale-up must progress in parallel.

The wrong partner may still complete the assigned tasks. The failure appears later, when the data do not support the intended claim, the clinical lot cannot be reproduced at scale, or a contract manufacturer discovers that the “finished” transfer package is not actually manufacturable.

What Do CDMO, CRO and CMO Mean in the IVD Industry?

These terms are commercial descriptions, not universal regulatory classifications. Two suppliers using the same label may have very different facilities, quality systems and technical capabilities.

The scope must therefore be defined by deliverables—not by the acronym.

What Is an IVD CDMO?

An IVD contract development and manufacturing organization combines product development with manufacturing services. Depending on its technical platform, an IVD CDMO may support:

Intended-use and product-requirement definition
Assay feasibility and optimization
Reagent formulation and conjugation
Primer, probe or antibody system development
Calibrator and control development
Lateral-flow strip or microfluidic cartridge development
Instrument, firmware and software integration
Design for manufacturability
Risk management and design documentation
Analytical performance studies
Design transfer
Pilot and engineering builds
Process validation
Stability programs
Packaging and labeling development
Regulatory submission support
Commercial manufacturing

A CDMO is especially useful when the product design and the production process must evolve together. In IVD development, this is often unavoidable. A reagent formulation that performs well at bench scale may react differently after bulk preparation, automated dispensing, drying, sealing, shipping or prolonged storage.

A capable CDMO does not merely reproduce a laboratory protocol. It converts that protocol into a controlled product and a reproducible manufacturing process.

What Is an IVD CRO?

An IVD contract research organization focuses primarily on research execution and evidence generation. Its work may include:

Clinical performance study design
Protocol and statistical analysis plan development
Study site identification and qualification
Ethics committee or institutional review board coordination
Specimen acquisition and management
Central laboratory services
Investigator and site training
Electronic data capture
Study monitoring
Data management and biostatistics
Medical or scientific writing
Clinical study reports
Regulatory submission support
Post-market performance studies

A diagnostics CRO may also conduct certain analytical studies, particularly when specialized specimens, independent laboratories or multi-site testing are required. However, analytical performance testing alone does not automatically make a laboratory a CRO. The relevant question is whether the organization has the quality, study-governance, data-integrity and regulatory capabilities needed for the intended evidence package.

For clinical performance studies using specimens from human subjects, ISO 20916:2019 defines good study practices for planning, conducting, recording and reporting the study. The standard also distinguishes clinical performance studies from analytical performance studies, an important boundary when assigning responsibilities.

What Is an IVD CMO?

An IVD contract manufacturing organization manufactures a product according to an established design and specification set. Typical services include:

Raw-material procurement
Incoming inspection
Reagent preparation
Dispensing, filling, drying or lyophilization
Strip, cartridge or kit assembly
Instrument assembly
In-process inspection
Final quality control
Packaging and labeling
Batch release support
Inventory management
Commercial-scale production
Distribution or logistics support

A CMO is most effective when the sponsor can provide a controlled and sufficiently complete manufacturing package. If formulations, tolerances, test methods, acceptance criteria or supplier specifications remain unresolved, the assignment is no longer pure contract manufacturing. It becomes a development and transfer program, whether or not the supplier calls itself a CDMO.

In the United States, FDA defines a contract manufacturer as an establishment that manufactures a finished device to another establishment’s specifications. Depending on the activities performed, contract manufacturers may also have their own establishment registration, device-listing and quality-system obligations.

IVD CDMO vs CRO vs CMO: The Core Differences

Decision area	IVD CDMO	IVD CRO	IVD CMO
Primary purpose	Develop the product and manufacturing process	Generate reliable research or clinical evidence	Manufacture an established product
Best entry point	Concept, feasibility or formal development	Evidence planning and study preparation	Late development, transfer or commercial production
Main uncertainty addressed	Whether the product can be made to meet its requirements	Whether the evidence supports the intended claims	Whether the product can be produced consistently at the required scale
Typical scientific role	Assay optimization, system integration and analytical development	Protocol execution, specimen operations, data management and statistics	In-process and final product testing
Typical manufacturing role	Pilot builds, scale-up, process development and commercial production	Study-lot handling or central-lab activities; usually limited manufacturing	Routine production and supply
Clinical study capability	Sometimes available, but must be verified	Usually a central capability	Rarely a core capability
Design-transfer capability	Core capability for a full-service CDMO	Limited	Strong only when the incoming package is mature
Most suitable product state	Evolving	Sufficiently defined for the planned study	Stable and controlled
Common commercial model	Milestones, development fees, NRE and manufacturing	Project fees, per-site fees, per-specimen fees and pass-through costs	Tooling, setup, MOQ and per-unit pricing
Major selection risk	Broad claims without deep platform expertise	Strong clinical operations but weak device-specific understanding	Attractive unit pricing based on an incomplete transfer package

These boundaries are not absolute. Some large organizations combine all three service models. Others specialize in a narrow platform, such as molecular diagnostics, immunoassays, clinical chemistry, digital pathology or point-of-care cartridges.

Capability overlap is useful, but it should never be assumed.

The Better Decision Rule: Follow the Unresolved Risk

A practical way to choose between an IVD CDMO, CRO and CMO is to identify the next uncertainty that could stop the program.

Ask three questions:

Is the device design or manufacturing process still uncertain?
If yes, the program needs CDMO capability.
Is the critical uncertainty related to specimens, study operations, clinical evidence or statistical conclusions?
If yes, the program needs CRO capability.
Is the product already defined, with the remaining challenge being repeatable supply, capacity, yield or cost?
If yes, a CMO may be sufficient.

This approach is more reliable than selecting a supplier from a generic service list. It also prevents a common mistake: appointing a manufacturing organization before the product has reached a transferable state.

Which Partner Do You Need at Each IVD Development Stage?

Development stage	Primary risk	Recommended lead partner	Important supporting capability
Intended use and product strategy	Developing the wrong product or claim	Sponsor with regulatory support; CDMO input	Market access and clinical expertise
Technical feasibility	Assay principle may not meet performance targets	IVD CDMO	Specimen access or specialist laboratory
Formal design and development	Prototype may not become a controlled product	IVD CDMO	Regulatory and quality assurance
Analytical performance evaluation	Data may not represent the final device	CDMO plus qualified internal or external laboratory	Biostatistics and specimen management
Clinical performance study	Evidence may not support the intended use	IVD CRO	CDMO-supplied representative study lots
Design transfer and process validation	Laboratory design may fail in production	IVD CDMO	Receiving CMO, if different
Regulatory submission	Evidence and manufacturing records may not form a coherent dossier	Legal manufacturer or submission owner	CDMO, CRO and regulatory specialists
Routine commercial production	Yield, quality, capacity or supply continuity may fail	CMO or commercial CDMO	Sponsor quality and supplier management
Post-market lifecycle management	Complaints, changes or new evidence may alter the risk-benefit profile	Depends on activity	CDMO, CRO and CMO may all participate

Stage 1: Intended Use, Claims and Development Strategy

Before selecting any development partner, the sponsor should define what the test is expected to do.

This includes:

Target condition or analyte
Intended population
Intended user
Specimen type
Testing environment
Qualitative, semi-quantitative or quantitative output
Proposed clinical claims
Expected regulatory classification and pathway
Target markets
Required turnaround time
Expected throughput
Preliminary cost and shelf-life targets

At this stage, the most important work still belongs to the product owner. A CDMO can test technical feasibility and challenge unrealistic requirements, but it should not independently decide the commercial or clinical purpose of the product.

A CRO may contribute early if specimen availability, recruitment feasibility or clinical workflow could determine whether the concept is viable. For example, a proposed claim may require a patient population that is difficult to recruit, or a reference method that is not routinely available at likely study sites.

A CMO normally should not lead this stage. It can, however, provide early feedback on likely production cost, raw-material availability and manufacturing constraints.

The main deliverable should be a preliminary target product profile or equivalent set of product requirements—not merely a list of desired assay characteristics.

Stage 2: Feasibility and Assay Development

Feasibility asks whether the proposed biological and technical principle can achieve the required performance.

This may involve:

Analyte and matrix characterization
Antibody, antigen, primer or probe screening
Reaction-condition optimization
Signal-system selection
Preliminary cut-off development
Interference and cross-reactivity exploration
Material compatibility
Prototype cartridge or strip construction
Instrument detection testing
Preliminary precision and sensitivity studies

An IVD CDMO is usually the best lead partner because decisions made during feasibility affect both product performance and future manufacturability.

A useful feasibility program does more than produce a favorable data set. It identifies the operating window and the likely failure mechanisms. A prototype that works under one carefully controlled condition is not yet a robust product.

Before moving into formal development, the sponsor should understand:

Which raw-material characteristics are critical
How much variation the assay can tolerate
Which process steps are likely to influence performance
Whether the available clinical matrix behaves like the development material
Whether the proposed format is compatible with automation
Whether preliminary stability supports the commercial concept
Whether target cost and scale remain plausible

A CRO may support specimen sourcing or specialized testing, but it rarely replaces the need for integrated assay and process development.

Stage 3: Formal Design and Development

Once feasibility has been demonstrated, the project moves from scientific exploration into controlled product development.

The work now needs to connect:

Design inputs
Design outputs
Risk controls
Verification activities
Clinical and analytical claims
Manufacturing specifications
Software or algorithm requirements
Packaging and labeling
Traceability between requirements and evidence

This is the stage where a full-service IVD CDMO provides the greatest value. It can develop the assay and the manufacturing process under the same quality framework, reducing the risk that manufacturing assumptions are introduced after the design is substantially frozen.

Risk management should also influence development decisions rather than being written retrospectively. ISO 14971:2019 provides the widely used lifecycle framework for identifying, evaluating, controlling and monitoring medical-device risks, including risks associated with IVDs.

The CDMO should begin defining critical material attributes and critical process parameters during this stage. Examples include:

Antibody or oligonucleotide identity and activity
Buffer pH and conductivity
Conjugation ratios
Dispense volume and positional accuracy
Membrane characteristics
Drying time and humidity
Lyophilization cycle parameters
Seal integrity
Calibration relationships
Optical or electronic tolerances
Software version and algorithm configuration

Waiting until design transfer to identify these variables turns transfer into another development program.

Stage 4: Analytical Performance Evaluation

Analytical performance determines how reliably the IVD measures or detects the target under defined conditions.

Depending on the technology and intended use, the study program may address:

Precision and reproducibility
Limit of blank
Limit of detection
Limit of quantitation
Measuring range
Linearity
Analytical specificity
Interference
Cross-reactivity
High-dose hook effect
Carryover
Method comparison
Specimen-type equivalence
Reagent and calibration stability
Usability-related performance
Flex studies for point-of-care or self-test products

The development CDMO often leads analytical verification because it understands the device design, failure modes and manufacturing variables. External laboratories or diagnostics CROs may be appropriate when the study requires independent execution, rare specimens, specialized equipment, multiple operators or multiple sites.

The most important issue is not who performs the study. It is whether the tested device is representative of the product that will be submitted and manufactured.

Analytical studies become vulnerable when they rely on:

Hand-built units that do not represent the intended process
A single unusually favorable reagent lot
Technology-grade materials that will not be used commercially
Uncontrolled software or algorithm versions
Non-final packaging
Artificial samples without adequate commutability justification
Acceptance criteria written after the results are known

Under the EU IVDR, performance evaluation is a lifecycle process built on scientific validity, analytical performance and clinical performance. The European Commission’s MDCG 2022-2 guidance emphasizes that the evidence must be collected, assessed and updated throughout the device lifecycle.

This means analytical development cannot be separated from intended use, clinical claims and risk management.

Stage 5: Clinical Performance Studies

A CRO usually becomes the operational lead when the program moves into a formal clinical performance study.

Typical CRO responsibilities include:

Study design consultation
Protocol development
Statistical analysis planning
Site feasibility and selection
Ethics or IRB coordination
Investigator agreements
Site initiation and training
Specimen accountability
Study monitoring
Data management
Deviation management
Database lock
Statistical analysis
Clinical study reporting

The CDMO still plays an important role. It must supply representative, traceable study lots; support device training; investigate technical complaints; control changes; and explain product-related deviations.

The study should not begin until the design is stable enough for the resulting evidence to remain relevant. If a later change affects the specimen pathway, reagent formulation, cut-off, instrument, algorithm or user workflow, the sponsor may need bridging data or additional performance studies.

For the United States, it is important not to assume that every IVD requires a prospective clinical trial. FDA states in its overview of IVD regulation that prospective clinical studies are rarely required for IVDs, but clinical samples with sufficient laboratory or clinical characterization are regularly needed to assess clinical validity or agreement.

The appropriate design depends on the device, claim, risk, specimen source, reference method and regulatory pathway.

Human-specimen governance must be addressed early. FDA’s IVD Good Clinical Practice guidance page notes that clinical investigations involving human specimens—including deidentified specimens—are subject to human-subject protection and IRB requirements, although specific informed-consent enforcement policies may apply in limited circumstances.

A CRO without deep IVD experience may underestimate these specimen-specific requirements. Pharmaceutical trial experience alone does not guarantee competence in diagnostic performance studies.

Stage 6: Design Transfer and Manufacturing Scale-Up

Design transfer is where a product stops being primarily an R&D object and becomes a controlled manufacturing system.

A credible transfer package may include:

Approved bill of materials
Raw-material specifications
Approved supplier requirements
Formulations and master preparation instructions
Drawings and component tolerances
Equipment and tooling requirements
Assembly procedures
In-process controls
Final release methods
Sampling plans
Acceptance criteria
Software and firmware configuration
Packaging and labeling specifications
Stability requirements
Storage and shipping conditions
Training requirements
Device history or batch-record templates
Known process risks and troubleshooting guidance

If these elements are incomplete, the receiving organization must perform development work. A CDMO is generally better equipped to close those gaps.

A conventional CMO can be appropriate when the sponsor already has a mature transfer package, validated methods and enough internal technical depth to manage the receiving site. It may also be suitable for a second-source transfer of an established product.

The transfer should include more than document delivery. Engineering batches, operator training, method transfer, equipment qualification, process characterization and acceptance criteria are needed to demonstrate that the receiving site can reproduce the intended product.

The most dangerous transfer is one that appears successful because a few pilot lots passed. A transfer is not robust until the process has been challenged across meaningful sources of variation.

Stage 7: Process Validation and Launch Readiness

At launch, the question changes from “Can we make acceptable product?” to “Can the defined process repeatedly produce acceptable product under routine conditions?”

The manufacturing partner may need to complete or support:

Equipment qualification
Process validation
Test-method validation or verification
Cleaning validation, where applicable
Packaging validation
Shipping validation
Operator qualification
Computerized-system validation
Reagent stability studies
Lot-to-lot comparability
Supplier qualification
Production capacity planning
Batch-release procedures
Traceability and record-retention controls

A commercial CDMO can carry the product from development into validated production with fewer handoffs. A CMO may offer lower unit costs or greater capacity, but only if the transfer and validation burden has been realistically included in the program.

In the United States, FDA’s Quality Management System Regulation became effective on February 2, 2026, incorporating ISO 13485:2016 by reference into 21 CFR Part 820. FDA explains the updated framework on its QMSR information page.

A supplier’s ISO 13485 certificate is therefore relevant, but it is not sufficient evidence of project fit. The sponsor should still evaluate the certification scope, audit history, technical competence, facility controls and experience with the specific IVD platform.

Stage 8: Routine Commercial Manufacturing

A CMO is often the logical lead when:

The device design is stable
Manufacturing documentation is complete
Test methods are established
Critical suppliers are qualified
Process parameters are known
Change frequency is low
Forecasts and service levels can be defined
The sponsor has sufficient supplier-quality oversight

At this point, procurement, capacity, yield, release timing and continuity of supply become dominant concerns.

A CDMO may remain preferable when:

The assay is unusually sensitive to biological raw-material variation
Frequent formulation or supplier changes are expected
Multiple regional versions are being introduced
The instrument, software and reagent system are tightly coupled
Post-market data are likely to drive further development
The sponsor lacks an internal technical operations team
Manufacturing problems require continuing development support

The lowest quoted unit price should not be treated as the lowest total cost. A cheaper CMO can become expensive if it requires a second technical team to investigate deviations, maintain the device history, manage changes or recover lost process knowledge.

Stage 9: Post-Market and Lifecycle Management

Commercial launch does not end development. It changes the source of information.

Post-market activities may identify:

New interference patterns
Population-specific performance differences
User-error trends
Raw-material drift
Stability limitations
Packaging or transport failures
Software defects
New safety signals
Opportunities for broader claims
Requirements for a new specimen type or instrument platform

The CMO or commercial CDMO provides manufacturing records, complaint-investigation support and trend data. The development CDMO may investigate root causes or implement design changes. A CRO may conduct post-market performance follow-up or additional evidence-generation studies.

Under the EU IVDR, performance evaluation and post-market performance follow-up are continuous lifecycle activities rather than one-time submission exercises. The partner model should therefore preserve access to development knowledge, raw data and manufacturing history after launch.

Three Baselines Must Stay Synchronized

IVD programs usually operate with three evolving baselines:

The design baseline: what the device is and how it is built.
The manufacturing baseline: how routine production controls the device.
The evidence baseline: which device version and claims are supported by the analytical and clinical data.

Many outsourcing failures are synchronization failures.

A CRO may test a device version that is no longer commercially relevant. A CMO may introduce a process change that has not been assessed against the clinical evidence. A CDMO may optimize the assay without updating labeling, risk analysis or validation requirements.

Every significant change should therefore be evaluated against all three baselines.

The change-control process should answer:

Does the change affect design inputs or intended use?
Could it alter analytical or clinical performance?
Does it affect a risk control?
Are existing verification or validation results still applicable?
Is bridging evidence required?
Does the change affect labeling or regulatory submissions?
Must study sites, distributors or authorities be notified?
Which party approves implementation?

This is one reason an integrated CDMO can reduce interface risk during development. It is also why an independent sponsor quality function remains necessary even when most execution is outsourced.

Outsourcing Does Not Transfer the Sponsor’s Regulatory Responsibility

A CDMO, CRO or CMO can perform regulated activities, but outsourcing does not automatically transfer the legal manufacturer’s obligations.

The legal manufacturer or submission owner generally remains responsible for ensuring that:

The device meets applicable regulatory requirements
The quality system covers outsourced activities
Suppliers are appropriately selected and controlled
Technical documentation is complete
Performance evidence supports the claims
Changes are assessed and approved
Complaints and reportable events are handled correctly
Post-market obligations are fulfilled

In the United States, a specification developer may use a contract manufacturer while remaining the party that submits the 510(k). FDA explicitly distinguishes the specification developer from the contract manufacturer in its 510(k) guidance.

A contract should assign tasks, authority and communication routes. It cannot make the sponsor indifferent to how the work is performed.

When One Integrated Partner Makes Sense

A single CDMO with development, clinical and commercial capabilities may be advantageous when:

The platform is technically complex
The sponsor has a small internal team
Speed depends on parallel development and scale-up
Clinical study devices must closely represent commercial production
The program requires tight coordination between reagents, instrument and software
Technology transfer would create significant delay or knowledge loss
The same organization can genuinely meet all quality and geographic requirements

Integration reduces the number of interfaces, but it also creates concentration risk. The sponsor should still evaluate whether the partner has real depth in every claimed function.

A useful test is to request separate capability reviews for:

Assay development
Manufacturing engineering
Quality systems
Clinical operations
Data management and statistics
Regulatory documentation
Commercial supply

If the same small group appears in every review, the organization may be offering a broad service menu without the specialized personnel required to execute it.

When Multiple Specialized Partners Are Better

A multi-partner model may be preferable when:

The assay requires a specialist development laboratory
Clinical studies require access to rare populations or geographic regions
Commercial volumes exceed the development partner’s capacity
The sponsor wants independent analytical or clinical evidence
A particular CMO has superior automation or unit economics
The product combines several technologies that no single supplier can support
Business continuity requires a qualified second source

The disadvantage is interface risk. Someone must own the integrated schedule, requirements, version control, change assessment and technical decisions.

When several suppliers are used, the sponsor needs a clear responsibility matrix covering:

Protocol ownership
Device and software versions
Study-lot manufacture and release
Specimen chain of custody
Raw-data ownership
Deviation investigation
Statistical programming
Manufacturing changes
Regulatory communications
Final report approval
Record retention

Without this governance, each supplier can complete its assigned scope while the overall evidence package remains inconsistent.

Questions to Ask an IVD CDMO

A serious CDMO evaluation should go beyond facility size and certification status.

Ask:

Which IVD platforms have you developed from feasibility through commercial production?
Which development activities are performed internally?
How do you connect design inputs, risk controls and verification plans?
How do you identify critical material attributes and process parameters?
Can you develop and validate QC methods?
How do you control biological raw-material variation?
Can you manufacture representative verification and clinical study lots?
Who owns formulations, methods, drawings, software and improvements?
What records will be transferred if the product moves to another manufacturer?
How are deviations and failed experiments documented?
What commercial volumes and batch sizes can you support?
How do you manage scale-up when the commercial process differs from the development process?
Which regulatory submissions have your teams supported?
Can your quality system support the intended markets?
What happens if a critical supplier changes or discontinues a material?

The partner should be able to describe not only successful programs, but also how it handled a difficult transfer, unstable raw material, failed validation or unexpected performance result.

Questions to Ask an IVD CRO

For a CRO, focus on evidence integrity and IVD-specific execution:

How many IVD performance studies have you managed?
Which analytes, technologies and specimen types are within your experience?
Can you support prospective, retrospective and leftover-specimen study designs?
How do you qualify sites and reference methods?
How do you verify specimen provenance and eligibility?
How are preanalytical variables controlled?
Who develops the statistical analysis plan?
How are missing data, invalid results and discordant results handled?
How do you control instrument, software and reagent-lot versions?
What electronic data capture and audit-trail systems are used?
How are protocol deviations classified and investigated?
Can you support IRB, ethics committee and competent-authority submissions?
Does the team work to ISO 20916 where applicable?
Who owns the database, statistical code and raw data?
How are study records retained and transferred?

A CRO should also explain how it would respond if device performance changed between study lots. That answer reveals whether the team understands IVD development or merely clinical project administration.

Questions to Ask an IVD CMO

For a CMO, evaluate the maturity of its manufacturing controls:

Is the proposed facility included within the relevant quality-system certification scope?
Has the site manufactured similar assay formats or biological materials?
Which operations are manual, semi-automated or automated?
What are the realistic minimum and maximum batch sizes?
Which process yields support the quoted unit price?
What incoming tests are performed on critical materials?
How are supplier and material changes communicated?
Can the CMO perform method transfer and test-method validation?
How are nonconforming materials and out-of-specification results investigated?
What are the batch-review and release timelines?
How are electronic records, software and equipment maintained?
What capacity is reserved, and what happens during demand surges?
What business-continuity plans cover equipment or supplier failure?
Can the CMO support regulatory inspections and technical-file questions?
What transition assistance is provided if manufacturing moves elsewhere?

A low unit price based on aggressive yield, insufficient testing or unrealistic forecasts is not a manufacturing advantage. It is an unpriced risk.

Contract Terms That Matter More Than the Acronym

The quality agreement and commercial agreement should clearly address:

Background and project-generated intellectual property
Ownership of formulations, methods and process improvements
Access to raw data and statistical code
Ownership of tooling and custom equipment
Audit rights
Regulatory inspection support
Supplier qualification
Change-notification periods
Deviation and CAPA responsibilities
Out-of-specification investigations
Complaint handling
Adverse-event and vigilance communication
Batch disposition authority
Record retention
Data-security requirements
Forecasting and capacity commitments
Minimum order quantities
Obsolescence and discontinuation
Technology-transfer assistance
Termination rights and transition support

The contract should also distinguish between commercially reasonable effort and a defined acceptance criterion. Development work contains uncertainty, but uncertainty should not make deliverables impossible to evaluate.

Common Partner-Selection Mistakes

Selecting a CMO Before the Product Is Transferable

The sponsor expects manufacturing, but the supplier discovers that methods, acceptance criteria and process tolerances are incomplete. Development work then appears as change orders, delays or unexpectedly high non-recurring engineering costs.

Starting Clinical Work Before the Device Is Stable

The CRO begins on schedule, but later design changes undermine the relevance of the data. The immediate schedule gain creates a larger regulatory delay.

Assuming the CDMO Can Perform Every Study Internally

Internal capability may improve coordination, but independence, site diversity, specialized specimens or qualified reference methods may still require an external laboratory or CRO.

Choosing by ISO Certificate Alone

ISO 13485 certification is important, but it does not demonstrate expertise in a specific assay technology, specimen type, manufacturing process or regulatory pathway.

Failing to Secure Data and Technology-Transfer Rights

The sponsor receives summary reports but cannot obtain editable methods, raw data, source files, process knowledge or supplier details. Switching manufacturers then becomes a partial redevelopment program.

Optimizing Unit Cost Before Stabilizing Yield

Early quotations often assume target yield rather than demonstrated yield. Until the process is characterized, the apparent unit cost may exclude scrap, failed batches, additional QC and long release cycles.

Practical Partner Choices for Common IVD Scenarios

A Startup Has a Biomarker Concept but No Product Design

Start with an IVD CDMO or specialized assay-development organization. Add a CRO when specimen strategy and clinical evidence planning become critical. A CMO is premature.

An RUO Assay Must Become a Regulated IVD

Use a CDMO for gap assessment, controlled redevelopment, design documentation, analytical verification and process development. The fact that an RUO assay works in expert hands does not prove that it can meet regulated product requirements.

A CRO may later support clinical performance evidence. A CMO should receive the program only after the regulated design and transfer package are sufficiently mature.

The Sponsor Has Strong Internal R&D but No Clinical Operations Team

The sponsor may retain assay development internally and appoint a CRO for protocol execution, sites, specimens, data management and biostatistics. A CDMO may still be needed for representative study-lot manufacture and scale-up.

A Mature IVD Needs a Second Manufacturing Source

A qualified CMO may be the best fit if the sponsor has complete documentation, validated methods and adequate internal transfer resources. Bridging, comparability and change assessment should be planned before transfer.

A Commercial Assay Requires a Major Reagent or Instrument Change

This is no longer a routine CMO assignment. A CDMO or internal development team should lead the technical change, with CRO support if new clinical evidence is required.

A Point-of-Care System Combines Assay, Cartridge, Reader and Software

An integrated CDMO is usually preferable during development because the components cannot be optimized independently. Specialized CRO support may be needed for intended-user studies and clinical performance evaluation.

Final Decision: CDMO, CRO or CMO?

Choose the organization that is equipped to resolve the next material program risk.

If the unresolved question is whether the assay and product can be developed into a manufacturable device, choose an IVD CDMO.
If the unresolved question is whether the evidence will support the intended clinical claim, choose an IVD CRO.
If the unresolved question is whether an established product can be manufactured consistently, economically and at the required scale, choose an IVD CMO.

Do not wait until the end of development to consider manufacturing. Do not start a clinical study simply because a prototype works. And do not assume that outsourcing execution transfers regulatory accountability.

The strongest IVD outsourcing strategy is usually a planned sequence: development with commercial manufacturing in mind, evidence generation using representative product, and production under a controlled process that preserves the validity of the supporting data.

That sequence—not the supplier’s acronym—is what turns an assay concept into a reliable commercial IVD.

Frequently Asked Questions

Is an IVD CDMO better than a CRO or CMO?

No. An IVD CDMO, CRO and CMO solve different problems. A CDMO is strongest in product and process development, a CRO in evidence generation and study execution, and a CMO in repeatable commercial manufacturing.

Can an IVD CDMO conduct clinical performance studies?

Some CDMOs can support or manage clinical studies, but the capability should be verified separately. Confirm access to qualified sites, specimen governance, study monitoring, data management, biostatistics and ISO 20916 experience where applicable.

Can a CRO perform analytical validation?

Some diagnostics CROs and central laboratories can conduct analytical performance studies. The appropriate provider depends on the test system, specimen requirements, equipment, regulatory purpose and required level of independence.

When should an IVD company select its commercial manufacturer?

Commercial manufacturing requirements should be considered during early development. The final manufacturer should ideally participate before design freeze so that equipment, process capability, QC methods, sourcing and scale constraints can influence the design.

When is a CMO sufficient for an IVD project?

A CMO may be sufficient when the product design, manufacturing documentation, test methods, acceptance criteria, suppliers and process controls are substantially established. If significant technical questions remain, CDMO capability is still required.

Does outsourcing manufacturing transfer regulatory responsibility?

No. The legal manufacturer or submission owner generally retains responsibility for device compliance, supplier controls, technical documentation, performance evidence, change control and post-market obligations.

Can one organization act as CDMO, CRO and CMO?

Yes, but the sponsor should audit each capability independently. A broad service portfolio does not guarantee equal depth in development science, clinical operations, data management and commercial manufacturing.

Should analytical and clinical studies use commercial-scale lots?

The lots should be sufficiently representative of the final device and intended manufacturing process. If earlier or pilot lots are used, the sponsor should document why the resulting data remain applicable and whether bridging studies are necessary.

When should a company move from a CDMO to a CMO?

The transition usually makes sense when the design and manufacturing process are stable, documentation is complete, methods are transferable, production economics justify the move and the sponsor has enough technical capacity to manage the transfer.

What is the most important factor when comparing IVD outsourcing partners?

The most important factor is alignment between the partner’s verified capabilities and the program’s unresolved risk. Certifications, facility size and quoted price matter, but none can compensate for choosing the wrong operating model at the wrong development stage.

Author Profile

IVDCDMO Team: Written by the IVDCDMO technical and regulatory team, with expertise in diagnostic assay development, GMP manufacturing, ISO 13485 systems, and global IVD commercialization for biotech innovators worldwide.